<DOC>
	<DOCNO>NCT02059876</DOCNO>
	<brief_summary>The purpose study determine efficacy safety dose-dense ( biweekly ) carboplatin paclitaxel ± trastuzumab neoadjuvant treatment early breast cancer .</brief_summary>
	<brief_title>Dose-dense ( Biweekly ) Carboplatin Plus Paclitaxel With Without Trastuzumab Neoadjuvant Treatment Breast Cancer</brief_title>
	<detailed_description>Dose-dense regimen show improve outcome give adjuvant therapy patient breast cancer compare three weekly counterpart . It unknown dose dense neoadjuvant therapy improve survival resectable breast cancer . This study evaluate efficacy safety dose-dense ( biweekly ) carboplatin paclitaxel ± trastuzumab neoadjuvant treatment early breast cancer . The endpoint pathologic complete response use surrogate marker survival . Safety tolerability assess number grade 4 toxicity hospitalization .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast carcinoma Clinical stage ⅡⅢB Patients must measurable disease define palpable lesion diameter ≥2cm measurable caliper and/or positive mammogram ultrasound least one dimension ≥2cm . Bilateral mammogram clip placement require study entry . Baseline measurement indicator lesion must record Patient Registration Form . To valid baseline , measurement must make within 14 day palpable . If palpable , mammogram MRI must do within 14 day . If palpable , mammogram MRI must do within 2 month prior study entry . If clinically indicate , xrays scan must do within 28 day study entry . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 within 14 day study entry Normal ( great 50 % ) leave ventricular ejection fraction ( LVEF ) echocardiography Signed informed consent Adequate organ function within 2 week study entry : 1 . Absolute neutrophil count &gt; 1500/mm3 , Hgb &gt; 9.0 g/dl platelet count &gt; 100,000/mm3 2 . Total bilirubin &lt; upper limit normal 3 . Creatinine &lt; 1.5 mg/dL calculate cranial cruciate ligament ( CrCL ) &gt; 50mL/min use Cockcroft Gault equation 4. serum glutamate oxaloacetate transaminase ( SGOT ) ( AST ) serum glutamic oxaloacetic transaminase ( SGPT ) ( ALT ) Alkaline Phosphatase must within range allow eligibility Patients must 18 year old . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Metastatic disease Prior chemotherapy , hormonal therapy , biologic therapy , investigational agent , target therapy radiation therapy current breast cancer . Patients history breast cancer great 5 year initial diagnosis eligible study . Patients may receive anthracyclinebased chemotherapy past . Patients history ductal carcinoma situ ( DCIS ) eligible treat surgery alone . History previous current malignancy site exception adequately treat carcinoma insitu cervix basal squamous cell carcinoma skin . Patients history malignancy , remain disease free great five year eligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>dose dense</keyword>
	<keyword>neoadjuvant treatment</keyword>
	<keyword>pathologic complete response</keyword>
</DOC>